Congratulations to our 2020 Endocrine Nurse Award winner
Join us in congratulating our 2020Endocrine Nurse Award winner, Sherwin Criseno, Advanced Nurse Practitioner/Lead Nurse Endocrinology at University Hospitals Birmingham NHS Trust.He was selected for his project entitled ‘An integrated approach to caring for older people: UHB-Lloyds Pharmacy Prolina Injection Project2 and will present on this atEndocrine Nurse Update 2020.TheSociety Endocrine Nurse Award aims to recognise individuals who have demonstrated innovative and successful nurse-led initiatives in the endocrine field that have advanced best practice in research, education or patient care.
This pro...
Source: Society for Endocrinology - August 2, 2019 Category: Endocrinology Source Type: news
Osteoporosis Dilemma: Denosumab or Teriparatide After Bisphosphonates Osteoporosis Dilemma: Denosumab or Teriparatide After Bisphosphonates
For osteoporosis patients on bisphosphonates for more than a year, switching to teriparatide rather than denosumab should be done with caution, especially for those at high risk of hip fracture, although denosumab has risks of its own, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 22, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Denosumab vs Bisphosphonates in Patients With Osteoporosis Denosumab vs Bisphosphonates in Patients With Osteoporosis
Denosumab and bisphosphonates are commonly used medications for the treatment of osteoporosis. Which is more effective?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 19, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Fracture-Risk Reduction Continues With Long-Term Denosumab Fracture-Risk Reduction Continues With Long-Term Denosumab
Extended treatment with denosumab is associated with continued reduction in nonvertebral fracture (NVF) rates, according to new findings.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - June 13, 2019 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news
Time to Update & quot;Routine, Repeated & quot; Use of Bone Metastasis Drugs Time to Update & quot;Routine, Repeated & quot; Use of Bone Metastasis Drugs
Dr Mark Kris discusses the use of zoledronic acid and denosumab for preventing problems brought on by bone metastases.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 2, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Amgen Reports First Quarter 2019 Financial Results
THOUSAND OAKS, Calif., April 30, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2019. Key results include:
Total revenues were unchanged at $5.6 billion in comparison to the first quarter of 2018.
Product sales declined 1 percent globally. New and recently launched products including Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib) showed double-digit growth.
GAAP earnings per share (EPS) decreased 2 percent to $3.18 driven by higher total operating expenses, offset partially by lower weighted-average shares outstanding.
...
Source: Amgen News Release - April 30, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Osteoporotic Fracture Rates Similar With Denosumab, Alendronate in Real World Osteoporotic Fracture Rates Similar With Denosumab, Alendronate in Real World
Rates of osteoporotic fracture were similar three years after starting either denosumab or alendronate in a real-world Danish population-based cohort study.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - April 26, 2019 Category: Orthopaedics Tags: Orthopaedics News Source Type: news
Denosumab cost effective in patients with multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 31, 2019 Category: Drugs & Pharmacology Source Type: news
New Guidelines Address Osteoporosis Treatment Postmenopause New Guidelines Address Osteoporosis Treatment Postmenopause
The Endocrine Society ' s new guidelines advise bisphosphonates and denosumab as first line for lower-risk women and anabolic treatments as first line for those at very high fracture risk.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 26, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
ONJ Rare After Dental Work While on Denosumab for Osteoporosis ONJ Rare After Dental Work While on Denosumab for Osteoporosis
The 7-year FREEDOM Extension trial found that postmenopausal women receiving denosumab for osteoporosis had a low risk of oral necrosis of the jaw (ONJ), even after major dental work.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 26, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Denosumab Plus AI Therapy Can Improve Outcomes in HR+ Breast Cancer
The addition of denosumab to adjuvant aromatase inhibitor therapy offered improved outcomes in women with postmenopausal HR+ early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 25, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Adjuvant Denosumab Improved DFS in HR+ Breast Ca
(MedPage Today) -- Results establish denosumab as alternative to bisphosphonates (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - February 24, 2019 Category: Endocrinology Source Type: news
Study Quantifies Dental, Jaw Risks With Denosumab
(MedPage Today) -- 10-year data suggest oral issues common (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - February 14, 2019 Category: Endocrinology Source Type: news
Rates of Osteonecrosis of the Jaw Low for Denosumab-Treated Women
THURSDAY, Feb. 14, 2019 -- For denosumab-treated women with postmenopausal osteoporosis, invasive oral procedures and events (OPEs), including dental implants, tooth extraction, natural tooth loss, scaling/root planning, and jaw surgery, are common... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 14, 2019 Category: Pharmaceuticals Source Type: news
Amgen Reports Fourth Quarter And Full Year 2018 Financial Results
THOUSAND OAKS, Calif., Jan. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key results include:
For the fourth quarter, total revenues increased 7 percent to $6.2 billion.
Product sales grew 8 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth.
For the full year, total revenues increased 4 percent to $23.7 billion, with 3 percent product sales growth...
Source: Amgen News Release - January 29, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
